OncoMatch/Clinical Trials/NCT06851299
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
Is NCT06851299 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including trop2-ADC and ADC +anti-angiogenic drug for metastatic triple-negative breast cancer.
Treatment: trop2-ADC · ADC +anti-angiogenic drug · ADC + PD1 monoclonal antibody +anti-angiogenic drug — This is a prospective, multicenter, randomized controlled study aimed at evaluating the efficacy and safety of Trop2-ADC monotherapy or immune combination strategy in the treatment of advanced triple-negative breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: radiotherapy
receiving radiotherapy...within 4 weeks before enrollment
Cannot have received: chemotherapy
receiving...chemotherapy...within 4 weeks before enrollment
Cannot have received: endocrine therapy
receiving...endocrine therapy within 4 weeks before enrollment
Cannot have received: interventional drug clinical trial
participating in any interventional drug clinical trial
Lab requirements
Blood counts
WBC ≥3.0×10^9 / L, ANC ≥1.5×10^9 / L, PLT ≥70×10^9 / L
Kidney function
Serum creatinine ≤1.5×ULN or creatinine clearance (Ccr) ≥60 ml/min
Liver function
Total bilirubin (TBIL) ≤3× ULN; ALT/AST ≤2.5×ULN (≤5xULN in patients with liver metastases)
Cardiac function
LVEF ≥ 55%, QTcF ≤ 470 ms
adequate bone marrow reserve: a. White blood cell count (WBC) ≥3.0×10^9 / L, b. Neutrophil count (ANC) ≥1.5×10^9 / L, c. Platelet count (PLT) ≥70×10^9 / L; liver, kidney and heart function tests were basically normal (according to the normal values of the laboratories in the study center) : a. Total bilirubin (TBIL) ≤3× ULN, b. ALT/AST ≤2.5×ULN (≤5xULN in patients with liver metastases), Serum creatinine ≤1.5×ULN or creatinine clearance (Ccr) ≥60 ml/min; d. LVEF ≥ 55%, e. QTcF ≤ 470 ms.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06851299 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy, chemotherapy, endocrine therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify